ePrints

A study of endothelial function and circulating asymmetric dimethylarginine levels in people with Type 1 diabetes without macrovascular disease or microalbuminuria

Lookup NU author(s): Dr Latika Sibal, Emeritus Professor Philip Home

Downloads

• Published version [.pdf]

Abstract

Background: Asymmetric dimethylarginine (ADMA) is a competitive inhibitor of endothelial nitric oxide synthase (eNOS) that is associated with endothelial dysfunction, and is a risk marker for cardiovascular disease, a significant problem in Type 1 diabetes. The aim of the present study was to measure circulating ADMA, and define its association with endothelial dysfunction and endothelial markers in people with Type 1 diabetes with low likelihood of macrovascular disease. Methods: Sixty-one young people with Type 1 diabetes without macrovascular disease or nephropathy and 62 healthy volunteers underwent brachial artery flow-mediated dilatation (FMD) and assay of plasma ADMA and adhesion molecules. Results: Age, gender, BMI, lipid profile and renal function were similar in the two groups. People with Type 1 diabetes had impaired FMD compared to healthy controls (5.0 +/- 0.4 vs 8.9 +/- 0.4%; p

Publication metadata

Author(s): Sibal L, Agarwal SC, Schwedhelm E, Luneburg N, Boger RH, Home PD

Publication type: Article

Publication status: Published

Journal: Cardiovascular Diabetology

Year: 2009

Volume: 8

Issue: 1

Pages: 27

Date deposited: 27/04/2010

ISSN (print): 1475-2840

ISSN (electronic):

Publisher: BioMed Central Ltd.

URL: http://dx.doi.org/10.1186/1475-2840-8-27

DOI: 10.1186/1475-2840-8-27

Altmetrics

Share